The Effects of Tualang Honey on Postmenopausal Women

OBJECTIVES

1. To evaluate the safety profile of honey in term of haematological and biochemical profile

• haematological function
• liver function
• renal function

1. To assess the changes in cardiovascular parameters

• blood pressure
• waist circumference
• total cholesterol
• high density lipoprotein
• low density lipoprotein
• fasting glucose

1. To assess the effects on hormonal level

• follicular stimulating hormone (FSH)
• luteinizing hormone (LH)
• testosterone
• estradiol

1. To assess the effects on bone density through bone densitometry (DEXA) scan measurement. Description of Methodology Study Subjects This is a randomized, prospective, clinical study to evaluate the effects of honey in comparison with hormone replacement therapy (HRT). Subjects will be confined to postmenopausal women. The study period will be four months, 41 subjects will be recruited for each group. A total of 82 patients will be recruited in this study. Eligible subjects consenting to participate will be randomly assigned to one of the two groups: GROUP 1: Subjects receiving 20 g/day of Tualang Honey GROUP 2: Subjects receiving hormonal replacement therapy (Femoston) Study Schedule About 10 ml of fasting blood samples will be collected for hormonal profiles at baseline and at the end of the study. The hormones to be assayed will be serum follicle stimulating hormone (FSH), Luteinising Hormone (LH), estradiol and total testosterone. Blood will also be taken for safety profile (haematology, liver function test and liver function test) and for cardiovascular parameters such fasting lipids and fasting blood sugar. Bone density will be check using Dual Energy X-ray Absorptiometry (DEXA) at baseline and end of the study. Subjects will be thoroughly examined by Medical Specialists who are part of the Clinical Trial Team at every 2-monthly visit. SAMPLE SIZE ESTIMATION The calculated sample size for the study is based on a standard statistical approach, often called as power calculations, which is widely used to calculate sample size in clinical trials. The formula is as below: N = p1 x (100 - p1) + p2 x (100-p2) x f (α, β) (p1 - p2) 2 In our pre-clinical trial (ovariectomised rat), about 40% increase in mean testosterone level was observed among the low dose group. Assuming a similar increase of ~10% is also obtained in the placebo group, and at a power of 80%, the calculated number of subjects per group would be 29. Taken into consideration that there will be about 40% drop-out rate, each treatment group would therefore be 41 subjects. Actual calculation: Set p1 = 40; p2 = 10; α β = 7.9 N = 40 (100-40) + 10 (100-10) x 7.9 = (40 x 60 + 10 x 90) x 7.9 (40-10)2 900 = 29

• 40% dropout = 29+ 12 =41 subjects per treatment arm There will be 2 groups, 41 subjects X 2 groups = Total of 82 patients need to be recruited. STUDY PROCEDURE Pre study screening Informed consent Healthy females, who have been considered for entry into the study, will be informed about the study and asked if they would like to participate. Subjects agreeing to participate must provide informed consent prior to any study specific assessments or procedures being informed. The study will be fully explained to the subject by the investigator. The investigator will provide the subject with a comprehensive explanation of the proposed treatment including , but not limited to, the nature of the therapy, alternative therapies, any known previously experienced adverse reactions, the investigational status of the tested extract and also the study aims, methods, anticipated benefits and potential hazards of the study, including any discomfort they may experience as a result of study participation. A summary of this information will also be provided to the subject in writing. The subject must have the opportunity to clarify with the Investigator any issues they did not understand and if necessary, ask further questions. The subject must be given adequate time to consider whether they wish to participate in the study. The subject must be informed that they are to withdraw consent at any time, without penalty or loss of benefits to which the patient is otherwise entitled. The investigator will obtain the subject's informed consent. The person, who obtains the informed consent, signed and dated the informed consent form. If this person is not the investigator, then the investigator must also sign and personally date the written informed consent form. A copy of the patient information sheet and the signed consent form must be provided to each subject. Screening procedures The following assessments were performed for all subjects during the screening process and recorded in the Clinical Record Form
• Subject initials
• Demographic details including weight and height
• Physical examination and investigations including pelvic ultrasonography and DEXA
• Brief medical history relating to past and current illnesses
• Concomitant medication
• Collect fasting blood sample for the following laboratory evaluations. Patient randomisation/blinding Subject will be randomized using Block Randomization. The assignment of Tualang Honey will be blinded to patients using ID numbers. Patient's withdrawal The investigator may cease study treatment and withdrew the subject or the subject may withdraw herself from participation in the study at any time. The reason for the withdrawal of a patient will be recorded in the CRF. Subject will be followed-up for a minimum of 30 days following the last dose of study drug. Possible reasons for patient withdrawal include:
• The need to take medication, which may interfere with study measurements.
• Patient experiences an intolerable / unacceptable adverse event
• Patient exhibits non-compliance with the protocol
• Patient unwilling to proceed and / or consent is withdrawn
• Investigator withdraws patient for reasons unrelated to the study drug (e.g. undercurrent illness) SAFETY ASSESSMENT Protocol specific clinical assessment Screening day and end of treatment Demographic details will be recorded at screening. The subject's body weight, blood pressure will be measured at 2 monthly periods. Medical history and adverse events At the screening visit, a physical examination will be conducted to determine the patient's current medical conditions and past clinically significant events. This includes all events that have occurred within the last three months and any other earlier event related to the inclusion and exclusion criteria or the subject's disease. This will be recorded at the screening visit. Throughout the study period, subject will be directly questioned about the occurrence of any new signs and symptoms and any changes from baseline will be recorded as an adverse event. Diary will be given to the patient to chart the proper timing and date for ingestion of honey. A physical examination will be repeated at the end of the treatment and exit evaluation to assist in determining if there had been any changes to the patient's health during the study period. Physical examination details will not be recorded in the CRF, unless there are changes from the baseline that warrant recording as a new adverse event or change to an existing adverse event. Vital signs All visits Vital signs (supine blood pressure, pulse rate) will be recorded at every visit. Patient is supine or semi-recumbent for five minutes prior to evaluating vital signs. Concomitant medication Concomitant medication included all co-administered drugs and treatment such as analgesics, tonics, herbals or traditional medicines and vitamin and/or mineral supplements. All concomitant medication taken within 7 days prior to commencement of study drug administration and for the duration of the study will be recorded in the CRF, including indication, dose, frequency, date and route administered. SAFETY REPORTING Adverse event definition An adverse event (AE) is defined as any untoward medical occurrence (including clinically significant laboratory findings) in a patient or clinical investigation subject administered a pharmaceutical drug, and which did not necessarily have a causal relationship to the treatment. Adverse event may include:
• The significant worsening of the disease or symptoms of the disease under investigation following administration of the drug
• Any undercurrent illness with an onset after administration of the drug
• Exacerbation (i.e. increase in frequency or intensity) of a pre-existing condition or event Serious adverse event definition A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose: Results in death
• Is life-threatening. A ' life-threatening' adverse event refers to an event, which puts the patient at risk of death. It does not refer to an event, which hypothetically might cause death if it is more severe.
• Requires in-patient hospitalization or prolongation of existing hospitalization. Hospitalization is defined as the patient being hospitalized overnight, or the patient's hospital stay being prolonged for at least an additional overnight stay. Hospital admissions for elective surgery, for social reasons or for normal disease management procedures that are not the result of the worsening of an underlying condition will not be considered a serious adverse event.
• Results in persistent or significant disability/incapacity
• Is a congenital anomaly/birth defect
• Is a malignancy
• Is the result of an overdose? An important medical event, which jeopardizes the patient and may require medical or surgical intervention to prevent one of the above outcomes from occurring. STATISTICAL ANALYSIS: Data will be entered, cleaned and analyzed using SPSS version 12. Means and standard deviations for numerical variables and frequency and proportion for categorical variables will be reported along with histogram or bar chart if necessary. For univariable analysis the independent t-test and one way ANOVA will be used to compare numerical outcome variables among the three treatment groups and chi square for categorical outcome variables. For mutivariable analysis, repeated measure ANOVA will be used for analysis to adjust for confounding variables. Level of significance is set at 5% and results will be presented with 95% confidence intervals.